1. Changing Paradigms in Relapsed/Refractory Indolent NHL

3. Unmet Medical Needs and Inferior Survival Identified in Some Patients With Indolent NHL

4. Case Scenario: FL

5. Biopsy at Relapse Is Key

6. Treatment Options for Early Relapse in FL

7. GALLIUM Trial: Obinutuzimab + CHOP vs Rituximab + CHOP in Relapsed FL

8. Factors in ASCT Decision-Making

9. Should You Use Rituximab Maintenance Post-ASCT?

10. Case Scenario: FL (cont)

11. Clinical Scenario: MZL

12. Treatment Options for Relapsed MZL

13. Ibrutinib Monotherapy in Relapsed MZL: Phase 2 Trial

14. Ibrutinib Monotherapy in MZL: Response Rates

15. RELEVANCE Trial: Lenalidomide + Rituximab in Untreated FL

16. AUGMENT Trial Schema

17. AUGMENT Trial Survival Data

18. AUGMENT: AEs in ≥ 15% of Patients

19. AUGMENT Trial: Responses in Patients With MZL

20. AUGMENT POD24 Data

21. Limited Role for Rituximab Monotherapy in the Relapsed Setting

22. AUGMENT QoL Analysis

23. PI3K Inhibitors in Indolent NHL

24. Serious Toxicities Associated With Idelalisib and Duvelisib

25. Copansilib in Indolent NHL

26. CHRONOS-1 Trial: AEs in ≥ 15 of Patients

27. Obinutuzumab as an Option

28. Emerging Agents: Tazemetostat in FL

29. Agents to Watch

30. FL Case Revisited

31. MZL Case Revisited

32. Concluding Remarks

33. Abbreviations

34. Abbreviations (cont)